

Proteomic characterization of spinal cord synaptoneurosomes from Tg-SOD1/G93A mice supports a role for MNK1 and local translation in the early stages of amyotrophic lateral sclerosis

Juan José Casañas, María Luz Montesinos*

Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, E-41009 Sevilla, Spain
 Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain

ARTICLE INFO

Keywords:

ALS
 iTRAQ
 Local translation
 MNK1
 SOD1
 Spinal cord

ABSTRACT

The isolation of synaptoneurosomes (SNs) represents a useful means to study synaptic events. However, the size and density of synapses varies in different regions of the central nervous system (CNS), and this also depends on the experimental species studied, making it difficult to define a generic protocol for SNs preparation. To characterize synaptic failure in the spinal cord (SC) in the Tg-SOD1/G93A mouse model of amyotrophic lateral sclerosis (ALS), we applied a method we originally designed to isolate cortical and hippocampal SNs to SC tissue. Interestingly, we found that the SC SNs were isolated in a different gradient fraction to the cortical/hippocampal SNs. We compared the relative levels of synaptoneurosomal proteins in wild type (WT) animals, with control (Tg-SOD1) or Tg-SOD1/G93A mice at onset and those that were symptomatic using iTRAQ proteomics. The results obtained suggest that an important regulator of local synaptic translation, MNK1 (MAP kinase interacting serine/threonine kinase 1), might well influence the early stages of ALS.

1. Introduction

Amyotrophic lateral sclerosis (ALS) is a fatal disease that affects both upper and lower motor neurons, producing muscular atrophy, paralysis and finally, death due to respiratory failure within 5 years of the first disease symptoms appearing, although 10–20 % of ALS patients have a survival longer than 10 years after diagnosis (Chio et al., 2009). Although in most cases the origin of ALS is unknown, 10 % of ALS cases are familial and of these, 20–25 % are due to dominant mutations affecting the SOD1 (superoxide dismutase 1) gene (Cleveland and Rothstein, 2001). Moreover, SOD1 has also been implicated in 1–2 % of the sporadic forms of ALS (Marangi and Traynor, 2015).

The neurotoxicity of SOD1 mutant proteins seems to be related to the acquisition of a new property, the aggregation and formation of protein inclusions (Shaw and Valentine, 2007). These protein aggregates are in line with the aggregates associated with other neurodegenerative diseases like Alzheimer's, Huntington's and Parkinson's disease. The tendency to form SOD1 aggregates seems to be restricted to motor neurons, as they do not appear in hippocampal or dorsal root ganglion (DRG) neurons transfected with mutant SOD1 constructs, only in transfected

motor neurons (Durham et al., 1997). Nevertheless, inclusions containing SOD1 protein are also found in astrocytes from ALS patients affected by familial SOD1 mutations (Kato et al., 2000). A number of hypotheses have been proposed to explain the toxicity of SOD1 aggregates in motor neurons, including: the co-aggregation of essential cytoplasmic proteins; the clogging of the proteasome with misfolded proteins; a depletion of chaperones; the dysfunction of mitochondria and other cellular organelles (reviewed by Boillée et al., 2006). However, it remains unclear if these phenomena are a cause or a consequence of the disease.

Among the various models of ALS developed, the Tg-SOD1/G93A (Gurney et al., 1994) transgenic mouse model is probably one of the best characterized. This transgenic line carries a mutant version of the human SOD1 gene in which the glycine at position 93 is replaced by alanine. Interestingly, dendrites with aggregates of the mutant SOD protein can initially be seen in Tg-SOD1/G93A mice at pre-symptomatic stages (Stieber et al., 2000), as also seen in other murine models of ALS (Vlug et al., 2005; Jaarsma et al., 2008). Significantly, dendritic aggregates have also been observed in tissue from individuals diagnosed with ALS (Arima et al., 1998; Kato et al., 2000). We previously found

* Corresponding author at: Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Av. Sánchez-Pizjuán 4, E-41009 Sevilla, Spain.

E-mail address: mlmontesinos@us.es (M.L. Montesinos).

<https://doi.org/10.1016/j.mcn.2022.103792>

Received 29 June 2022; Received in revised form 3 November 2022; Accepted 6 November 2022

Available online 11 November 2022

1044-7431/© 2022 Elsevier Inc. All rights reserved.

hippocampal synaptoneurosomes (SNs) to be strongly enriched in SOD1 mRNA, suggesting that it could be translated locally in dendrites (unpublished data). Accordingly, FMRP (Fragile-X mental retardation protein), a key local regulator of translation (Darnell and Klann, 2013), has been shown to activate SOD1 translation (Bechara et al., 2009). Finally, SOD1 mutations in the 3'UTR (untranslated region) have been linked to ALS (Shaw et al., 1997; Ince et al., 1998). It is known that motifs in the 3'UTR regulate the transport, stability and local translation of dendritic mRNAs (reviewed by Andreassi and Riccio, 2009). In fact, evidence is accumulating that supports a role for RNA metabolism in ALS, not least since many genes mutated in ALS are RNA-binding proteins, including TDP-43 (Neumann et al., 2006), FUS (Kwiatkowski et al., 2009; Vance et al., 2009), ATXN2 (Elden et al., 2010), hnRNPA1 and hnRNPA2/B1 (Kim et al., 2013). Indeed, the inclusions from ALS patients contain RNA and RNA-binding proteins (reviewed by Wolozin and Ivanov, 2019). Together, these observations suggest that altered local dendritic mRNA translation could be one of the initial events involved in ALS motor neuron degeneration.

As a first step to investigate this hypothesis, we used here an improved protocol to obtain spinal cord (SC) SNs that we had originally designed to isolate cortical and hippocampal SNs (Troca-Marín et al., 2010). Remarkably, SC SNs were located in a different fraction to that of the hippocampal SNs, which we characterized both biochemically and by electron microscopy (EM).

Proteomic analyses have been previously performed in ALS mice models (including Tg-SOD1/G93A) and human ALS tissue (Gershoni-Emek et al., 2016; Engelen-Lee et al., 2017; Lum et al., 2022; Zhang et al., 2022). However, these studies were focused on total SC or brain, or in presynaptic fractions derived from these tissues. To our knowledge, no previous proteomic analysis has been carried out on SC SNs (i.e., fractions enriched in pre- and post-synaptic elements) from ALS models. Thus, using isobaric tags for relative and absolute quantitation (iTRAQ) proteomics, we compared the relative levels of proteins in SC SNs from WT mice to those from Tg-SOD1 control mice and Tg-SOD1/G93A mice at the onset of their symptoms and in symptomatic mice. A significant number of the affected proteins in the samples at onset are targets of the MAP kinase interacting serine/threonine kinase 1 (MKNK1, also known as MNK1), a protein that acts in the Ras-ERK signaling pathway and that also influences FMRP-regulated mRNA translation. In fact, reduced levels of MNK1 were measured in SC SNs from Tg-SOD1/G93A mice. Finally, we found that the rates of translation in SNs from the SC were decreased at the onset of the Tg-SOD1/G93A phenotype. Overall, our results suggest that deregulated local synaptic translation controlled by MNK1 might play a role in the early stages of ALS.

2. Materials and methods

2.1. Animals

B6SJL-Tg(SOD1)2Gur/J (Tg-SOD1) and B6SJL-Tg(SOD1*G93A) 1Gur/J (Tg-SOD1/G93A) mice (Gurney et al., 1994) were obtained from Jackson Laboratories, and they were maintained on a mixed genetic background as recommended, breeding hemizygous male carriers with B6SJL/F1 females. These B6SJL/F1 females were obtained by crossing C57BL/6J females with SJL/JOrlCrl males (Charles River, France). The criteria used to classifying the Tg-SOD1/G93A animals as at disease onset or symptomatic are summarized in Table S1 (Supplemental File 1). Taking into account these criteria, ages of onset animals used in this study were P87–114, and symptomatic animals were P120–P139.

2.2. SN isolation

SNs were isolated as described previously (Troca-Marín et al., 2010). Briefly, the SC from 6 to 9 mice was dissected out rapidly, put together and homogenized with a glass-teflon Dounce homogenizer in 12 ml of

homogenization buffer: 10 mM Hepes [pH 7.4]; 320 mM sucrose; 1.0 mM MgSO₄; protease inhibitors leupeptin (10 μM), aprotinin (2 μg/ml) and pepstatin (1 μM). The homogenate was centrifuged at 1000 g for 10 min at 4 °C and the resulting pellet (P1) was resolved on an Optiprep discontinuous gradient (consisting in steps of 9 %, 12.5 %, 15 %, 25 % and 40 % Optiprep). Four bands (O1 to O4; Fig. 1A) were obtained after centrifugation at 16,500 g for 30 min at 4 °C. The fractions O1 and O2 were recovered and passed separately through a discontinuous Percoll gradient (consisting in steps of 10 %, 14 %, 16 %, 20 % and 25 % Percoll). After centrifugation at 32,400 g for 20 min at 4 °C, five bands were obtained from fraction O1 and O2: 1P1 to 1P5 (Fig. 1A) and 2P1 to 2P5, respectively (data not shown). Of these, fraction 1P5 corresponds to the SC SNs.

2.3. SC protein extracts

Total lumbar SC protein extracts were prepared using a mechanical overhead stirrer (Heidolph model RZR 2020) with a 2 ml Potter-Elvehjem PTFE pestle. The tissue was homogenized in the following extraction buffer: 50 mM Tris buffer [pH 7.4], 0.5 % Triton X-100, 150 mM NaCl, 1 mM EDTA, 3 % SDS, protease inhibitor cocktail (1:100 dilution, P8340: Sigma), phosphatase inhibitor cocktail 2 (1:100 dilution, P5726: Sigma), and phosphatase inhibitor cocktail 3 (1:100 dilution, P0044: Sigma). The samples were then centrifuged for 15 min at 15,279 g using a bench-top microfuge at room temperature, and the supernatants were recovered.

2.4. Western blotting

To characterize the SC fractions obtained through the SN isolation protocol previously described (Troca-Marín et al., 2010), B6SLJF1 mice were used. The samples from pellet P1, fractions O1 and O2, and the Percoll fractions 1P1 to 1P5, and 2P1 to 2P5, were first resolved by SDS-PAGE using Mini-PROTEAN® TGX precast gels (BioRad). The proteins were then transferred to polyvinylidene difluoride (PVDF) membranes overnight (tank blotting), stained with SYPRO® Ruby protein blot stain (Invitrogen), and the SYPRO Ruby signal was measured in a ChemiDoc XRS (BioRad) imager and used for normalization. In other experiments, Western blotting was carried out following a similar protocol but Mini-PROTEAN® TGX Stain-Free™ precast gels (BioRad) were used. After electrophoresis, the gels were UV irradiated in a ChemiDoc XRS apparatus (BioRad) to induce the reaction of trihalo compounds in the gel with the tryptophan residues of the proteins. The resulting fluorescent signal was proportional to the total protein present in the gel, and it was measured and used for normalization.

The membranes were probed with the primary antibodies against: CSP-α (R-807, rabbit polyclonal antiserum, a gift from Dr. Rafael Fernández-Chacón, Universidad de Sevilla-IBiS, Spain); GRIA2 (anti-GluA2/AMPA2#1, rabbit polyclonal antiserum, Cat. No. 182103: Synaptic Systems); gephyrin (3B11 mouse monoclonal antibody, Cat. No. 147111: Synaptic Systems); GRIA1 (anti-GluA1/AMPA1, rabbit polyclonal antiserum, Cat. No. 182003: Synaptic Systems); DAG1 (43DAG1/8D5 mouse monoclonal antibody, Product code NCL-b-DG: Novocastra); and Mnk1 (C4C1, antibody #2195: Cell Signaling Technology). The binding of HRP-conjugated secondary antibodies was revealed by ECL Plus (GE Healthcare Life Sciences) and chemiluminescence was measured using a ChemiDoc XRS apparatus (BioRad). The linearity of the chemiluminescent signals was determined in pilot experiments for each antibody using 2-fold dilutions of a protein sample. The linearity of the SYPRO Ruby signal and the trihalo/tryptophan-produced fluorescence was also assessed similarly.

2.5. Electron microscopy (EM)

Material from the SC 1P5 fraction of B6SLJF1 mice was pelleted and fixed for 1 h at 4 °C with 2 % glutaraldehyde in 0.1 M cacodylate buffer




Fig. 1. SC SNs isolation. (A) Optiprep and Percoll gradients from a typical SC SN isolation. Four subcellular fractions (O1 to O4) were obtained after the Optiprep gradient and when the material from the O1 fraction was separated on a Percoll gradient, five bands were observed (1P1 to 1P5). The SNs were found in fraction 1P5. (B) Quantification of synaptic proteins in the Percoll gradient fractions from the mouse SC. Levels of direct chemiluminescence for the CSP- α , GRIA2 and gephyrin proteins detected in P1, O1 and O2, and in the corresponding Percoll gradient fractions (1P1 to 1P5 from O1 and 2P1 to 2P5 from O2), normalized to the total protein in the samples. Normalized chemiluminescence for P1 was arbitrarily set to 1. Three independent experiments were performed. A representative experiment is shown (for images see Supplemental Fig. 1). Note that the GRIA2 levels for fractions O2 and 2P1 to 2P5 were not determined.

(pH 7.4) for EM. The sample was then washed with cacodylate, secondarily fixed in 1 % OsO₄, gradually dehydrated and embedded in Spurr resin. Sections were acquired at 80 kV on a ZEISS LIBRA 120 transmission electron microscope (TEM) at the CITIUS Microscopy Service (Universidad de Sevilla).

2.6. iTRAQ labeling and analysis

SC SNs were isolated from WT mice (littermates of Tg-SOD1/G93A animals that did not bear the transgene), from Tg-SOD1/G93A mice that had just started to show some muscle weakness (G93A-ONSET) and from overtly symptomatic animals (G93A-SYMPOM). In order to control for any changes due to overexpression of the human SOD1 transgene, SNs were also isolated from Tg-SOD1 mice.

Protein extraction, iTRAQ labeling (using AB ScieX, Ref. 4390811) and tandem mass spectrometry (MS) analysis was carried out at the Instituto de Biomedicina de Sevilla (IBiS) Proteomics Service, as described previously (Urbano-Gómez et al., 2021). Two sets of samples were included in the 8-plex experiment. In Set 1, 50 μ g of the protein extract was labeled for each experimental condition, whereas Set 2 contained different amounts of protein in order to check the linearity of the procedure. Only Set 1 was considered in this work and the data were analyzed with the Proteome Discoverer 1.4 software (Thermo), setting a

False Discovery Rate (FDR) for both protein and peptide identification as <0.01.

2.7. Gene Ontology and pathway analyses

PANTHER version 17.0 (Mi et al., 2016) overrepresentation tests were performed on line (<http://www.pantherdb.org>), selecting the entire *Mus musculus* genome (21,997 proteins) and applying a Bonferroni correction for multiple testing. Only proteins identified with at least two unique peptides were included. An Ingenuity Pathway Analysis (IPA) core analysis was performed for both up- and downregulated proteins, considering a 2-fold cut-off threshold. Only proteins identified with at least two unique peptides were included in the IPA and the Ingenuity Knowledge Base (genes only) set was used as a reference, considering direct and indirect relationships. All the molecules and/or relationships analyzed were observed experimentally, either in the mouse, rat or human nervous system tissue or in cells (astrocytes or neurons). The IPA software generates networks composed of sets of up to 35 functionally-related proteins and each network is attributed a score (maximum score = 50). Only the most significant networks (score > 25) were considered here.

2.8. Radioactive labeling of SNs

SNs were resuspended in SN buffer (Huang and Richter, 2007) that was supplemented with chloramphenicol (100 µg/ml) to inhibit the mitochondrial synthesis of proteins, as described previously (Huang and Richter, 2007; Troca-Marín et al., 2010). The samples were incubated for 30 min at 37 °C in the presence of the EasyTag Express Protein Labeling Mix 35S (PerkinElmer), pelleted, washed with SN buffer and resolved by SDS-PAGE on Mini-PROTEAN® TGX Stain-Free™ precast gels (BioRad). After electrophoresis, the gels were exposed to UV irradiation in a ChemiDoc XRS apparatus (BioRad) and the resulting fluorescent signal was used for normalization. The proteins were then

transferred to PVDF membranes overnight, and the radiolabeled proteins were detected and quantified using a Cyclone Plus Phosphor Imager system (PerkinElmer).

2.9. Statistical analysis

The quantitative data are presented as the mean ± SEM and the significance of the comparisons was assessed using a Student's *t*-test (SigmaStat software).




Fig. 2. Electron micrographs of the 1P5 subcellular fraction. Pre-synaptic (pre) and post-synaptic (post) elements are marked, and the mitochondria (mit), synaptic vesicles (asterisk) and post-synaptic densities (arrows) can be distinguished. Panels 1 to 5 are zoom images from top left panel image.




Fig. 3. PANTHER overrepresentation tests of proteins detected in SC SNs byiTRAQ. The cellular components (A), pathways (B) and protein classes (C) enriched >4-fold in SC SNs are shown.

3. Results

3.1. SC SNs are found in an unexpected gradient fraction

We had previously reported an improved method for SN preparation (Troca-Marín et al., 2010) in which the homogenized tissue is subjected to isopycnic centrifugation on a discontinuous Optiprep gradient and some of the subcellular fractions obtained are then separated in Percoll gradients. When the mouse hippocampus or neocortex is used as the starting material, the SN enriched fraction corresponds to the 1P4 fraction (Troca-Marín et al., 2010), that is the fourth Percoll gradient band obtained from processing the first Optiprep gradient fraction (O1). To test whether this protocol was suitable to isolate SNs from the SC, the subcellular fractions O1, O2, 1P1 to 1P5 (Percoll gradient of O1) and 2P1 to 2P5 (Percoll gradient of O2) obtained from the SCs of adult mice were characterized in Western blots (Fig. 1A). CSP- α was used as pre-synaptic marker, whereas GluA2 and gephyrin were used as excitatory and inhibitory post-synaptic markers, respectively. Somewhat surprisingly, the strongest enrichment of pre- and post-synaptic proteins was evident not in the 1P4 but in the 1P5 fraction (Fig. 1B; Supplemental Fig. 1). Indeed, TEM analysis of the material in the SC 1P5 fraction showed it was enriched in SNs. Notably, in these preparations the pre- and post-synaptic elements remained attached, and synaptic vesicles and mitochondria were abundant in the pre-synaptic terminal (Fig. 2).

3.2. Characterization of the proteins present in SC SNs

The iTRAQ analysis carried out identified 3133 proteins in SC SNs with at least one unique peptide (see below), applying a FDR = 0.01 (Table S2 in Supplemental File 1). Of these, 1652 were identified with at least two unique peptides (Table S3 in Supplemental File 1) and were considered for PANTHER analysis. 1353 proteins were mapped to IDs in the PANTHER gene ontology tool. We carried out overrepresentation tests to classify these proteins according to different criteria: molecular function, protein class, cell component, pathways and biological processes in which these proteins are involved (Supplemental File 2). There was a significant representation of proteins from synapses, the cytoskeleton and the ATP synthase complex in the SC SNs (Fig. 3). As such, SC SNs were enriched in proteins involved in the tricarboxylic acid (TCA) cycle and other oxidative metabolic processes, in cytoskeletal organizers and in proteins involved in synaptic signaling (for example, through metabotropic and ionotropic glutamate receptors, or dopamine, serotonin and acetylcholine receptors), as well as in proteins with other functions (Fig. 3 and Supplemental File 2). Overall, these results corroborated the 1P5 fraction as the biochemical fraction enriched in SNs.

Interestingly, protein folding was among the list of outstanding biological processes, and chaperones, aminoacyl-tRNA synthetases and translational proteins were among the protein classes enriched in SC SNs (Fig. 3 and Supplemental File 2).

3.3. Relative protein levels in SC SNs from Tg-SOD1 mice, and Tg-SOD1/G93A mice at disease onset and symptomatic

To characterize the progress of SC synaptic failure in the ALS mouse model Tg-SOD1/G93A, we compared the relative levels of SN proteins at disease onset and in symptomatic Tg-SOD1/G93A animals. We isolated SC SNs from WT mice (littermates of Tg-SOD1/G93A animals that did not bear the transgene), from Tg-SOD1/G93A-ONSET mice in which the first signs of the disease have just appeared), and from overtly symptomatic Tg-SOD1/G93A-SYMPATOM animals. To control the effects associated to human SOD1 overexpression, SC SNs from Tg-SOD1 mice were also studied. These preparations were analyzed by iTRAQ proteomics and the amount of each protein relative to the WT SNs was defined

(Table S2 in Supplemental File 1). Only proteins identified with at least two unique peptides were considered for quantitative analysis with the IPA software (1652 proteins: Table S3 in Supplemental File 1), and a 2-fold cut-off was established to identify the most prominent protein changes. Using this criterion, only 5 proteins were found to be strongly deregulated in Tg-SOD1 SNs (3 up- and 2 down-regulated: Table S4 in Supplemental File 3). In the Tg-SOD1/G93A-ONSET sample, 69 proteins were affected (2 up- and 67 down-regulated: Table S5 in Supplemental File 3, while in the SNs from the Tg-SOD1/G93A-SYMPATOM mice the levels of most of these proteins (1387 proteins) was altered (3 up- and 1384 down-regulated: Table S6 in Supplemental File 3). To confirm these results, we examine the amount of the glutamate ionotropic receptor AMPA type 1 subunit (GRIA1) and dystroglycan 1 (DAG1) in Western blots of WT and Tg-SOD1/G93A-ONSET SNs. As expected, the levels of these proteins were reduced in Tg-SOD1/G93A-ONSET SNs (Supplemental Fig. 2).

While no relevant network of altered proteins was found in Tg-SOD1 SNs, two networks gave high scores in Tg-SOD1/G93A-ONSET SNs. Of these, Network 1 (score = 27) mainly included proteins involved in cell death and RNA expression (Fig. 4A), whereas the proteins in Network 2 (score = 25) essentially participate in defining the morphology of neurons, movement disorders and in neuromuscular disease (Fig. 4B). Interestingly, the IPA revealed that MNK1 was the most statistically significant upstream regulator (Z-score = -2.449, *p* value of overlap = 7.5E-06), suggesting that MNK1 downregulation could explain many of the protein alterations observed in Tg-SOD1/G93A-ONSET SC SNs.

MNK1 is a kinase in the Ras-ERK signaling pathway that is involved in local translation and it mediates the BDNF-induced release of CYFIP1 from eIF4E in cortical neurons, triggering protein synthesis (Genheden et al., 2015). Indeed, these authors found that the synthesis of 718 proteins appeared to be regulated by MNK1 and given that CYFIP1 interacts with FMRP (Napoli et al., 2008), a significant overlap between these MNK1 regulated proteins and 842 high-confidence FMRP targets (Darnell et al., 2011) was detected (Genheden et al., 2015). Thus, we compared the complete list of MNK1-regulated proteins (Genheden et al., 2015) and the list of high-confidence FMRP-regulated proteins (Darnell et al., 2011) with the list of proteins deregulated in Tg-SOD1/G93A-ONSET SC SNs. Remarkably, 22 proteins affected in Tg-SOD1/G93A-ONSET SC SNs (i.e.: 31.9 %) were identified as MNK1 targets, and 8 proteins (i.e.: 11.6 %) were identified as FMRP targets (Table 1). These data suggest a possible role of MNK1 (and/or FMRP) in the onset of ALS.

As most proteins were affected in the Tg-SOD1/G93A-SYMPATOM SC SNs, it would appear that there was a general perturbation of synaptic proteins, probably related to the motor neurodegeneration that is characteristic of advanced ALS stages. Accordingly, IPA predicted an impairment in synaptic transmission and in the transport of synaptic vesicles (SVs), as well as enhanced neurodegeneration in these mice (not shown).

3.4. A reduction in the MNK1 protein in SC SNs from Tg-SOD1/G93A mice at the onset of the disease

The IPA analysis suggested that reduced levels and/or activity of MNK1 could be responsible for the proteomic changes in Tg-SOD1/G93A-ONSET SC SNs. As the MNK1 protein was not detected in the iTRAQ experiments, we quantified the amount of MNK1 protein in Western blots of SNs from WT and Tg-SOD1/G93A-ONSET mice. As predicted by the IPA, reduced MNK1 levels were detected in the Tg-SOD1/G93A-ONSET SNs relative to the WT SNs (Fig. 5A). This reduction was specific to the synaptic preparations as it was not observed in the total protein extracts (Fig. 5B).

A




Fig. 4. Networks of proteins affected in Tg-SOD1/G93A-ONSET SC SNs. (A) Network 1 (score = 27) is comprised of 35 proteins, of which 18 were downregulated (green) in Tg-SOD1/G93A-ONSET SNs. The proteins in grey were also present in Tg-SOD1/G93A-ONSET SC SNs but they were unaffected considering a 2-fold cut-off. Continuous lines represent direct relationships between proteins and the discontinuous lines indicate indirect relationships. Proteins outlined in red are MNK1 targets, those outlined in blue are regulated by FMRP. In this network, 17 proteins are known to be involved in RNA expression, including MBP, NONO, SFPQ, SIRT2, SORBS3 and TRIM28. In addition, 26 proteins of this network are known to be involved in cell death, including BIN1, CACNA1C, CCT2, DAG1, LAMA1, MBP, RAP1GDS1, SFPQ, SIRT2, THBS1 and TRIM28. (B) Network 2 (score = 25) is comprised of 35 proteins, of which 16 were downregulated (green) and 1 was upregulated (red) in Tg-SOD1/G93A-ONSET SNs. The proteins in grey were also present in Tg-SOD1/G93A-ONSET SC SNs but they were unaffected considering a 2-fold cut-off. Continuous lines represent direct relationships between proteins and discontinuous lines indicate indirect relationships. The proteins outlined in red are MNK1 targets, those outlined in blue are regulated by FMRP, and the proteins outlined in orange are regulated by MNK1 and FMRP. There were 14 proteins in this network known to be involved in movement disorders, including AGRN, APBA1, CIT, CORO2B, DTNA and TUBB4B. Moreover, 12 proteins in this network are known to be involved in neuronal morphology, including AGRN, APBA1, CLTC, DTNA, FLNA and HNRNPA2B1.

B




Table 1

Proteins altered in G93A-ONSET SC SNs known to be regulated by MNK1 or FMRP.

MNK1 targets	
AGRN	Agrin
CAPN2	Calpain 2
CCT2	Chaperonin containing TCP1 subunit 2
CCT5	Chaperonin containing TCP1 subunit 5
CLTC	Clathrin heavy chain
DAG1	Dystroglycan 1
FLNA	Filamin A
FLNB	Filamin B
HNRNPA1	Heterogeneous nuclear ribonucleoprotein A1
HNRNPA2B1	Heterogeneous nuclear ribonucleoprotein A2/B1
HNRNPA3	Heterogeneous nuclear ribonucleoprotein A3
HNRNPC	Heterogeneous nuclear ribonucleoprotein C (C1/C2)
LAMC1	Laminin subunit gamma 1
NONO	Non-POU domain containing, octamer-binding
PSPC1	Paraspeckle component 1
SFPQ	Splicing factor proline/glutamine-rich
SIRT2	Sirtuin 2
TAGLN	Transgelin
TUBB4B	Tubulin beta 4B class IVb
VCL	Vinculin
VIM	Vimentin
VPS35	VPS35 retromer complex component
FMRP targets	
AGRN	Agrin
APBA1	Amyloid beta precursor protein binding family A member 1
CAMTA1	Calmodulin binding transcription activator 1
CIT	Citron rho-interacting serine/threonine kinase
CLTC	Clathrin heavy chain
DTNA	Dystrobrevin alpha
MBP	Myelin basic protein
SORBS2	Sorbin and SH3 domain containing 2

3.5. Lower rates of translation in SC SNs from Tg-SOD1/G93A-ONSET mice

Since MNK1 is involved in local synaptic translation, we analyzed translation in SC SNs from Tg-SOD1/G93A mice. As such, metabolic labeling revealed an average 30 % reduction in the translation rate in G93A-ONSET SC SNs (mean translation rate 69.6 ± 4.5 %, $n = 7$) relative to WT SC SNs (Fig. 6). A similar reduction in metabolic labeling was also evident in SC SNs from symptomatic mice (mean translation rate 66.0 ± 15 %, $n = 2$), whereas normal or even enhanced labeling was seen in Tg-SOD1 SC SNs (Fig. 6). In conclusion, these data suggest that local synaptic translation is impaired in the Tg-SOD1/G93A SC at early stages of the disease.

4. Discussion

Since their initial description (Hebb and Whittaker, 1958), SNs have been used extensively to explore different aspects of synaptic physiology. Indeed, >14,000 publications can be retrieved from PubMed by searching with the word “synaptoneurosome”. Generic protocols are often used to isolate SNs regardless of the specie (mouse, rat or other) or the nervous system region studied, two factors that will critically affect the outcome. Here we show that, using the protocol we originally established to isolate SNs from the mouse hippocampus and cortex, SC SNs (as characterized biochemically and morphologically) localize to a different gradient fraction.

Through iTRAQ proteomics, we found that mitochondrial, synaptic and cytoskeletal proteins were among the most strongly represented proteins in SC SNs, as previously reported in other proteomics studies focused on synaptic cortical preparations (for example see Witzmann et al., 2005; Benito et al., 2018). Interestingly, we found that chaperonins and chaperones, especially those belonging to the Hsp70 family, were particularly overrepresented in SC SNs. Remarkably, Hsp70




Fig. 5. Levels of MNK1 protein are reduced in SC SNs but not in the total protein extracts of Tg-SOD1/G93A-ONSET mice. (A) Proteins from WT and Tg-SOD1/G93A-ONSET SC SNs were analyzed in Western blots probed with an anti-MNK1 antibody. The signals obtained were normalized to the total protein loaded. Total protein was measured as fluorescent signal after gel exposition to UV (see Materials and methods section). The mean values are shown, with the number of independent SN preparations indicated in the corresponding bars. The error bars indicate the SEM and the asterisk denotes a statistically significant difference ($p = 0.039$, t -test). A representative Western blot is shown. (B) Proteins from WT and Tg-SOD1/G93A-ONSET SC total extracts were analyzed in Western blots probed with an anti-MNK1 antibody. The signals obtained were normalized to the total protein loaded and the mean values are shown, with the number of independent total protein extracts analyzed indicated in the corresponding bar. The error bars indicate the SEM and a representative Western blot is shown.

chaperones (and their Hsp40 partners) fulfil an important role in translation, associating with polysomes and enhancing translation by promoting the folding of nascent peptides (reviewed by Walters and Parker, 2015). In relation to this, aminoacyl-tRNA synthetases were also overrepresented in SC SNs, which could reflect the relevant role of these enzymes in translation at SC synapses, as is indeed the case in hippocampus (Benito et al., 2018). Hence, it is tempting to speculate that local translation could be particularly important for motor neurons and consequently, motor neurons could be particularly sensitive to any defects in local translation.

Since ALS is diagnosed when the first clinical manifestations appear, we were interested in determining the proteins that experienced alterations early in the disease. Thus, we focused on Tg SOD1/G93A mice at the onset of the symptoms. Strikingly, of the 69 proteins altered in SC SNs from Tg-SOD1/G93A-ONSET mice, many of them were involved in the processing or binding of mRNA and/or translation. In fact, we found that a significant percentage of the affected proteins were targets of MNK1, a key regulator of local dendritic translation. MNK1 was predicted by IPA to be the most significant upstream regulator of the set of proteins altered in Tg-SOD1/G93A-ONSET SC SNs and it was predicted




Fig. 6. Local synaptic translation is reduced in the SC of Tg-SOD1/G93A-ONSET mice. (A) ^{35}S -Met/Cys radioactive labeled proteins in the SC SNs from symptomatic Tg-SOD1/G93A-SYMPATOM mice, Tg-SOD1/G93A-ONSET mice at disease onset (ONSET 1 and 2), and from wild type (WT) and Tg-SOD1 mice. Similar amounts of protein were loaded for each condition and a representative experiment is shown. (B) Quantification of the radioactive, neosynthesized proteins in WT, Tg-SOD1 and Tg-SOD1/G93A SC SNs from three independent experiments. The radioactivity incorporated into neosynthesized proteins was quantified in SC SNs obtained from WT ($n = 5$), Tg-SOD1 ($n = 3$) and Tg-SOD1/G93A-ONSET ($n = 7$) or Tg-SOD1/G93A-SYMPATOM ($n = 2$) mice, normalized to the total protein content of the corresponding sample. The data are shown as the percentages compared to the WT values and the asterisks indicate significant difference between Tg-SOD1/G93A-ONSET and WT SNs ($p = 0.0065$, t -test).

to be downregulated in the SC SNs from these mice. MNK1 was not detected in the iTRAQ experiments. It is well known that MS-based proteomics is inherently prone to stochastic peptide sampling (as is the case for most high-throughput technologies), leading to missing values (Hogrebe et al., 2022). Although iTRAQ palliates this problem by multiplexing, missing values still represents a technical limitation, especially for relatively low expression proteins (Luo and Zhao, 2012). In fact, it has been reported that missing values can range from 5 to 50 %

in any given iTRAQ experimental replicate (Luo and Zhao, 2012; Gardner and Freitas, 2021).

However, by Western blot, we found less MNK1 protein in SC SNs as well as reduced local translation rates (measured as the radioactive labelling of neosynthesized proteins in SNs).

Among the proteins identified, several were of particular interest in the context of ALS. Thus, mutations in the mRNA binding proteins HnRNPA1, HnRNPA2/B1 or HnRNPA3 seem to cause ALS (Kim et al., 2013; Fifita et al., 2017). In addition, the retromer complex subunit VPS35 has recently been seen to be reduced in motor neurons of asymptomatic and symptomatic G93A mice, and in ALS patients. Indeed, retromer stabilization by increasing VPS35 levels ameliorates the phenotype of G93A mice (Muzio et al., 2020).

It is well known that, in response to BDNF or glutamate, local translation is activated through two related pathways: the Akt-mTOR and the Ras-ERK pathways (reviewed by Swanger and Bassell, 2013). MNK1 functions in the Ras-ERK branch, phosphorylating eIF4E and thereby triggering translation. In addition, MNK1 activation disrupts the inhibitory complex formed by CYFIP1 and eIF4E, triggering the translation of specific targets (Genheden et al., 2015). Thus, in basal conditions FMRP tethers target mRNAs to CYFIP1, which blocks eIF4E and prevents the initiation of translation (Napoli et al., 2008). TrkB or mGluR activation provokes the MNK1-dependent release of CYFIP1 from eIF4E, inducing the translation of some FMRP targets (Napoli et al., 2008; Genheden et al., 2015). Therefore, the reduced synaptic levels of MNK1 detected in Tg-SOD1/G93A-ONSET mice may not only affect general local translation but more specifically, FMRP-regulated local translation. As proposed previously (Genheden et al., 2015), the complex molecular relationships described above could explain the significant overlap between MNK1 and FMRP targets. Indeed, we found that a number of FMRP targets were also affected in SC SNs from Tg-SOD1/G93A-ONSET mice (Table 1). As mentioned, FMRP acts primarily as a translational repressor but it has also been demonstrated to directly activate SOD1 translation by binding to a particular structural motif located in the SOD1 5'UTR, the SoSLIP motif (Bechara et al., 2009). Given the molecular relationships between MNK1 and FMRP (Genheden et al., 2015), and between FMRP and SOD1 (Bechara et al., 2009), it is tempting to speculate that aberrant dendritic SOD1 translational complexes in Tg-SOD1/G93A-ONSET mice might sequester FMRP (and perhaps chaperones), which could interfere with translation of other FMRP target mRNAs, MNK1 targets and/or with local translation in general. In ALS mouse models, aberrant SOD1 aggregates first appear in dendrites (Stieber et al., 2000; Vlug et al., 2005; Jaarsma et al., 2008) and dendritic aggregates have also been described in ALS patients (Arima et al., 1998; Kato et al., 2000). Interestingly, it has been reported that WT and mutant SOD1/G93A proteins localize to stress granules and P-bodies, and that SOD1/G93A inclusions also contain mRNAs (Da Ros et al., 2021). Although the precise molecular mechanisms responsible for the reduced synaptic levels of MNK1 remain to be elucidated, our findings point to an important role of MNK1 and local translation in the early stages of ALS. Thus, MNK1 could represent a potential therapeutic target in ALS.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mcn.2022.103792>.

Funding

This work was supported by the Junta de Andalucía (Grant P09-CTS-4610).

CRediT authorship contribution statement

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Juan José Casañas. Proteomics data analysis was performed by María Luz Montesinos. The manuscript was written by María Luz Montesinos. All

authors read and approved the final manuscript.

Ethics approval

All the experiments performed here were carried out in accordance with the European Union directive (2010/63/EU) for the protection of the animals used for research purposes. All the protocols were approved by the Regional Government (Junta de Andalucía, Spain) Ethics Committee.

Declaration of competing interest

The authors have no relevant financial or non-financial interests to disclose.

Data availability

This manuscript has data included as electronic supplementary material.

Acknowledgements

We thank Juan Luis Ribas (CITIUS, Microscopy Service, Universidad de Sevilla, Spain) and Mariló Pastor (IBiS Proteomics Service, Instituto de Biomedicina de Sevilla, Spain) for their technical help and advice. We also thank the Supercomputing and Bioinnovation Center (Universidad de Málaga, Spain) for providing us with access to the IPA tool.

References

- Andreassi, C., Riccio, A., 2009. To localize or not to localize: mRNA fate is in 3'UTR ends. *Trends Cell Biol.* 19, 465–474. <https://doi.org/10.1016/j.tcb.2009.06.001>.
- Arima, K., Ogawa, M., Sunohara, N., Nishio, T., Shimomura, Y., Hirai, S., Eto, K., 1998. Immunohistochemical and ultrastructural characterization of ubiquitinated eosinophilic fibrillary neuronal inclusions in sporadic amyotrophic lateral sclerosis. *Acta Neuropathol.* 96, 75–85. <https://doi.org/10.1007/s004010050862>.
- Bechara, E.G., Didiot, M.C., Melko, M., Davidovic, L., Bensaid, M., Martin, P., Castets, M., Pognonec, P., Khandjian, E.W., Moine, H., Bardoni, B., 2009. A novel function for fragile X mental retardation protein in translational activation. *PLoS Biol.* 7, e16 <https://doi.org/10.1371/journal.pbio.1000016>.
- Benito, I., Casañas, J.J., Montesinos, M.L., 2018. Proteomic analysis of synaptoneuroosomes highlights the relevant role of local translation in the hippocampus. *Proteomics* 18, e1800005. <https://doi.org/10.1002/pmic.201800005>.
- Boillée, S., Vande Velde, C., Cleveland, D.W., 2006. ALS: a disease of motor neurons and their nonneuronal neighbors. *Neuron* 52, 39–59. <https://doi.org/10.1016/j.neuron.2006.09.018>.
- Chio, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., Eurals Consortium, 2009. Prognostic factors in ALS: a critical review. *Amyotroph. Lateral Scler.* 10, 310–323. <https://doi.org/10.3109/17482960802566824>.
- Cleveland, D.W., Rothstein, J.D., 2001. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. *Nat. Rev. Neurosci.* 2, 806–819. <https://doi.org/10.1038/35097565>.
- Da Ros, M., Deol, H.K., Savard, A., Guo, H., Meiering, E.M., Gibbins, D., 2021. Wild-type and mutant SOD1 localizes to RNA-rich structures in cells and mice but does not bind RNA. *J. Neurochem.* 156, 524–538. <https://doi.org/10.1111/jnc.15126>.
- Darnell, J.C., Klann, E., 2013. The translation of translational control by FMRP: therapeutic targets for FXS. *Nat. Neurosci.* 16, 1530–1536. <https://doi.org/10.1038/nn.3379>.
- Darnell, J.C., Van Driesche, S.J., Zhang, C., Hung, K.Y., Mele, A., Fraser, C.E., Stone, E.F., Chen, C., Fak, J.J., Chi, S.W., Licatalosi, D.D., Richter, J.D., Darnell, R.B., 2011. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* 146, 247–261. <https://doi.org/10.1016/j.cell.2011.06.013>.
- Durham, H.D., Roy, J., Dong, L., Figlewicz, D.A., 1997. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. *J. Neuropathol. Exp. Neurol.* 56, 523–530. <https://doi.org/10.1097/00005072-199705000-00008>.
- Elden, A.C., Kim, H.J., Hart, M.P., Chen-Plotkin, A.S., Johnson, B.S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M.M., Padmanabhan, A., Clay-Falcone, D., McCluskey, L., Elman, L., Jühr, D., Gruber, P.J., Rüb, U., Auburger, G., Trojanowski, J.Q., Lee, V.M., Van Deerlin, V.M., Bonini, N.M., Gitler, A.D., 2010. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* 466, 1069–1075. <https://doi.org/10.1038/nature09320>.
- Engelen-Lee, J., Blokhuis, A.M., Spliet, W.G.M., Pasterkamp, R.J., Aronica, E., Demmers, J.A.A., Broekhuizen, R., Nardo, G., Bovenschen, N., Van Den Berg, L.H., 2017. Proteomic profiling of the spinal cord in ALS: decreased ATP5D levels suggest synaptic dysfunction in ALS pathogenesis. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 18, 210–220. <https://doi.org/10.1080/21678421.2016.1245757>.
- Fifita, J.A., Zhang, K.Y., Galper, J., Williams, K.L., McCann, E.P., Hogan, A.L., Saunders, N., Bauer, D., Tarr, I.S., Pamphlett, R., Nicholson, G.A., Rowe, D., Yang, S., Blair, I.P., 2017. Genetic and pathological assessment of hnRNPA1, hnRNPA2/B1, and hnRNPA3 in familial and sporadic amyotrophic lateral sclerosis. *Neurodegener. Dis.* 17, 304–312. <https://doi.org/10.1159/000481258>.
- Gardner, M.L., Freitas, M.A., 2021. Multiple imputation approaches applied to the missing value problem in bottom-up proteomics. *Int. J. Mol. Sci.* 22, 9650. <https://doi.org/10.3390/ijms22179650>.
- Genheden, M., Kenney, J.W., Johnston, H.E., Manousopoulou, A., Garbis, S.D., Proud, C. G., 2015. BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1. *J. Neurosci.* 35, 972–984. <https://doi.org/10.1523/JNEUROSCI.2641-14.2015>.
- Gershoni-Emek, N., Mazza, A., Chein, M., Gradus-Pery, T., Xiang, X., Li, K.W., Sharan, R., Perlson, E., 2016. Proteomic analysis of dynein-interacting proteins in amyotrophic lateral sclerosis synaptosomes reveals alterations in the RNA-binding protein Staufen1. *Mol. Cell. Proteomics* 15, 506–522. <https://doi.org/10.1074/mcp.M115.049965>.
- Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X., 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. *Science* 264 (5166), 1772–1775. <https://doi.org/10.1126/science.8209258>.
- Hebb, C.O., Whittaker, V.P., 1958. Intracellular distributions of acetylcholine and choline acetylase. *J. Physiol.* 142, 187–196. <https://doi.org/10.1113/jphysiol.1958.sp006008>.
- Hogrebe, A., Hess, K.N., Llovet, A., Ramos, Y.J., Barente, A.S., Hernandez-Portugues, D., Smith, I.R., Rodríguez-Mias, R.A., Villén, J., 2022. IsobaricQuant enables cross-platform quantification, visualization, and filtering of isobarically-labeled peptides. *Proteomics*, e2100253. <https://doi.org/10.1002/pmic.202100253>.
- Huang, Y.S., Richter, J.D., 2007. Analysis of mRNA translation in cultured hippocampal neurons. *Methods Enzymol.* 431, 143–162. [https://doi.org/10.1016/S0076-6879\(07\)31008-2](https://doi.org/10.1016/S0076-6879(07)31008-2).
- Ince, P.G., Tomkins, J., Slade, J.Y., Thatcher, N.M., Shaw, P.J., 1998. Amyotrophic lateral sclerosis associated with genetic abnormalities in the gene encoding Cu/Zn superoxide dismutase: molecular pathology of five new cases, and comparison with previous reports and 73 sporadic cases of ALS. *J. Neuropathol. Exp. Neurol.* 57, 895–904. <https://doi.org/10.1097/00005072-199810000-00002>.
- Jaarsma, D., Teuling, E., Haasdijk, E.D., De Zeeuw, C.I., Hoogenraad, C.C., 2008. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. *J. Neurosci.* 28 (9), 2075–2088. <https://doi.org/10.1523/JNEUROSCI.5258-07.2008>.
- Kato, S., Takikawa, M., Nakashima, K., Hirano, A., Cleveland, D.W., Kusaka, H., Shibata, N., Kato, M., Nakano, I., Ohama, E., 2000. New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: inclusions containing SOD1 in neurons and astrocytes. *Amyotroph. Lateral Scler. Other Motor Neuron Disord.* 1, 163–184. <https://doi.org/10.1080/14660820050515160>.
- Kim, H.J., Kim, N.C., Wang, Y.D., Scarborough, E.A., Moore, J., Diaz, Z., MacLea, K.S., Freibaum, B., Li, S., Mollie, A., Kanagaraj, A.P., Carter, R., Boylan, K.B., Wojtas, A. M., Rademakers, R., Pinkus, J.L., Greenberg, S.A., Trojanowski, J.Q., Traynor, B.J., Smith, B.N., Topp, S., Gkazi, A.S., Miller, J., Shaw, C.E., Kottlors, M., Kirschner, J., Pestronk, A., Li, Y.R., Ford, A.F., Gitler, A.D., Benatar, M., King, O.D., Kimonis, V.E., Ross, E.D., Weihl, C.C., Shorter, J., Taylor, J.P., 2013. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. *Nature* 495, 467–473. <https://doi.org/10.1038/nature11922>.
- Kwiatkowski Jr., T.J., Bosco, D.A., Leclerc, A.L., Tamrazian, E., Vanderburg, C.R., Russ, C., Davis, A., Gilchrist, J., Kasarskis, E.J., Munsat, T., Valdmanis, P., Rouleau, G.A., Hosler, B.A., Cortelli, P., de Jong, P.J., Yoshinaga, Y., Haines, J.L., Pericak-Vance, M.A., Yan, J., Ticozzi, N., Siddique, T., McKenna-Yasek, D., Sapp, P. C., Horvitz, H.R., Landers, J.E., Brown Jr., R.H., 2009. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science* 323, 1205–1208. <https://doi.org/10.1126/science.1166066>.
- Lum, J.S., Berg, T., Chisholm, C.G., Vendruscolo, M., Yerbury, J.J., 2022. Vulnerability of the spinal motor neuron presynaptic terminal sub-proteome in ALS. *Neurosci. Lett.* 778, 136614 <https://doi.org/10.1016/j.neulet.2022.136614>.
- Luo, R., Zhao, H., 2012. Protein quantitation using iTRAQ: review on the sources of variations and analysis of nonrandom missingness. *Stat. Interface* 5, 99–107. <https://doi.org/10.4310/sii.2012.v5.n1.a9>.
- Marangi, G., Traynor, B.J., 2015. Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges. *Brain Res.* 1607, 75–93. <https://doi.org/10.1016/j.brainres.2014.10.009>.
- Mi, H., Poudel, S., Muruganujan, A., Casagrande, J.T., Thomas, P.D., 2016. PANTHER version 10: expanded protein families and functions, and analysis tools. *Nucleic Acids Res.* 44 (D1), D336–D342. <https://doi.org/10.1093/nar/gkv1194>.
- Muzio, L., Sirtori, R., Gornati, D., Eleuteri, S., Fossaghi, A., Brancaccio, D., Manzoni, L., Ottoboni, L., Feo, L., Quattrini, A., Mastrangelo, E., Sorrentino, L., Scalone, E., Combi, G., Marinelli, L., Riva, N., Milani, M., Seneci, P., Martino, G., 2020. Retromer stabilization results in neuroprotection in a model of amyotrophic lateral sclerosis. *Nat. Commun.* 11, 3848. <https://doi.org/10.1038/s41467-020-17524-7>.
- Napoli, I., Mercurio, V., Boyl, P.P., Eleuteri, B., Zalfa, F., De Rubis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., Witke, W., Costa-Mattioli, M., Sonenberg, N., Achsel, T., Bagni, C., 2008. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. *Cell* 134, 1042–1054. <https://doi.org/10.1016/j.cell.2008.07.031>.

- Neumann, M., Sampathu, D.M., Kwong, L.K., Truax, A.C., Micsenyi, M.C., Chou, T.T., Bruce, J., Schuck, T., Grossman, M., Clark, C.M., McCluskey, L.F., Miller, B.L., Masliah, E., Mackenzie, I.R., Feldman, H., Feiden, W., Kretzschmar, H.A., Trojanowski, J.Q., Lee, V.M., 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 314, 130–133. <https://doi.org/10.1126/science.1134108>.
- Shaw, P.J., Tomkins, J., Slade, J.Y., Usher, P., Curtis, A., Bushby, K., Ince, P.G., 1997. CNS tissue Cu/Zn superoxide dismutase (SOD1) mutations in motor neurone disease (MND). *Neuroreport* 8, 3923–3927. <https://doi.org/10.1097/00001756-199712220-00016>.
- Shaw, B.F., Valentine, J.S., 2007. How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? *Trends Biochem. Sci.* 32, 78–85. <https://doi.org/10.1016/j.tibs.2006.12.005>.
- Stieber, A., Gonatas, J.O., Gonatas, N.K., 2000. Aggregates of mutant protein appear progressively in dendrites, in periaxonal processes of oligodendrocytes, and in neuronal and astrocytic perikarya of mice expressing the SOD1(G93A) mutation of familial amyotrophic lateral sclerosis. *J. Neurol. Sci.* 177, 114–123. [https://doi.org/10.1016/s0022-510x\(00\)00351-8](https://doi.org/10.1016/s0022-510x(00)00351-8).
- Swanger, S.A., Bassell, G.J., 2013. Dendritic protein synthesis in the normal and diseased brain. *Neuroscience* 232, 106–127. <https://doi.org/10.1016/j.neuroscience.2012.12.003>.
- Troca-Marín, J.A., Alves-Sampaio, A., Tejedor, F.J., Montesinos, M.L., 2010. Local translation of dendritic RhoA revealed by an improved synaptoneurosome preparation. *Mol. Cell. Neurosci.* 43, 308–314. <https://doi.org/10.1016/j.mcn.2009.12.004>.
- Urbano-Gómez, J.D., Casañas, J.J., Benito, I., Montesinos, M.L., 2021. Prenatal treatment with rapamycin restores enhanced hippocampal mGluR-LTD and mushroom spine size in a Down's syndrome mouse model. *Mol. Brain* 14, 84. <https://doi.org/10.1186/s13041-021-00795-6>.
- Vance, C., Rogelj, B., Hortobágyi, T., De Vos, K.J., Nishimura, A.L., Sreedharan, J., Hu, X., Smith, B., Ruddy, D., Wright, P., Ganesalingam, J., Williams, K.L., Tripathi, V., Al-Saraj, S., Al-Chalabi, A., Leigh, P.N., Blair, I.P., Nicholson, G., de Belleruche, J., Gallo, J.M., Miller, C.C., Shaw, C.E., 2009. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science* 323, 1208–1211. <https://doi.org/10.1126/science.1165942>.
- Vlug, A.S., Teuling, E., Haasdijk, E.D., French, P., Hoogenraad, C.C., Jaarsma, D., 2005. ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis-SOD1 transgenic mice and correlates with c-Jun phosphorylation, CHOP expression, somato-dendritic ubiquitination and golgi fragmentation. *Eur. J. Neurosci.* 22, 1881–1894. <https://doi.org/10.1111/j.1460-9568.2005.04389.x>.
- Walters, R.W., Parker, R., 2015. Coupling of ribostasis and proteostasis: Hsp70 proteins in mRNA metabolism. *Trends Biochem. Sci.* 40, 552–559. <https://doi.org/10.1016/j.tibs.2015.08.004>.
- Witzmann, F.A., Arnold, R.J., Bai, F., Hrnčirova, P., Kimpel, M.W., Mechref, Y.S., McBride, W.J., Novotny, M.V., Pedrick, N.M., Ringham, H.N., Simon, J.R., 2005. A proteomic survey of rat cerebral cortical synaptosomes. *Proteomics* 5, 2177–2201. <https://doi.org/10.1002/pmic.200401102>.
- Wolozin, B., Ivanov, P., 2019. Stress granules and neurodegeneration. *Nat. Rev. Neurosci.* 20, 649–666. <https://doi.org/10.1038/s41583-019-0222-5>.
- Zhang, J., Wen, A., Chai, W., Liang, H., Tang, C., Gan, W., Xu, R., 2022. Potential proteomic alteration in the brain of Tg(SOD1*G93A)1Gur mice: a new pathogenesis insight of amyotrophic lateral sclerosis. *Cell Biol. Int.* 46, 1378–1398. <https://doi.org/10.1002/cbin.11842>.